Special Issue

COVID-19 Vaccine Candidate Development

Message from the Guest Editors

In light of the considerable amount of work carried out in the field of vaccine technologies over the last years, much is to be learnt from the recent experiences of many research groups in vaccine design and testing, which may constitute a valuable resource for the future. We are pleased to invite you to contribute to this Special Issue of *Vaccines*, entitled "COVID-19 vaccine candidate development". In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: COVID-19 candidate vaccine design, construction and trials, and refinements or innovations regarding vaccine testing, both in animal models and in human clinical trials.

Guest Editors

Dr. Rafael Blasco

Dr. Javier Ortego

Dr. Alejandro Marin-Lopez

Deadline for manuscript submissions

closed (31 March 2023)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/119228

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

